QQQ   444.48 (-0.25%)
AAPL   175.04 (-2.57%)
MSFT   415.02 (-0.12%)
META   498.75 (-0.71%)
GOOGL   133.49 (-2.66%)
AMZN   177.94 (-0.16%)
TSLA   188.96 (-6.75%)
NVDA   855.60 (+3.99%)
NIO   5.40 (-6.57%)
AMD   206.96 (+2.13%)
BABA   72.02 (-3.48%)
T   16.76 (-1.30%)
F   12.80 (+2.81%)
MU   96.40 (+1.31%)
CGC   3.03 (-5.61%)
GE   160.85 (+1.39%)
DIS   113.80 (+1.65%)
AMC   4.31 (-1.15%)
PFE   25.85 (-2.78%)
PYPL   60.17 (-0.61%)
XOM   104.16 (-1.59%)
QQQ   444.48 (-0.25%)
AAPL   175.04 (-2.57%)
MSFT   415.02 (-0.12%)
META   498.75 (-0.71%)
GOOGL   133.49 (-2.66%)
AMZN   177.94 (-0.16%)
TSLA   188.96 (-6.75%)
NVDA   855.60 (+3.99%)
NIO   5.40 (-6.57%)
AMD   206.96 (+2.13%)
BABA   72.02 (-3.48%)
T   16.76 (-1.30%)
F   12.80 (+2.81%)
MU   96.40 (+1.31%)
CGC   3.03 (-5.61%)
GE   160.85 (+1.39%)
DIS   113.80 (+1.65%)
AMC   4.31 (-1.15%)
PFE   25.85 (-2.78%)
PYPL   60.17 (-0.61%)
XOM   104.16 (-1.59%)
QQQ   444.48 (-0.25%)
AAPL   175.04 (-2.57%)
MSFT   415.02 (-0.12%)
META   498.75 (-0.71%)
GOOGL   133.49 (-2.66%)
AMZN   177.94 (-0.16%)
TSLA   188.96 (-6.75%)
NVDA   855.60 (+3.99%)
NIO   5.40 (-6.57%)
AMD   206.96 (+2.13%)
BABA   72.02 (-3.48%)
T   16.76 (-1.30%)
F   12.80 (+2.81%)
MU   96.40 (+1.31%)
CGC   3.03 (-5.61%)
GE   160.85 (+1.39%)
DIS   113.80 (+1.65%)
AMC   4.31 (-1.15%)
PFE   25.85 (-2.78%)
PYPL   60.17 (-0.61%)
XOM   104.16 (-1.59%)
QQQ   444.48 (-0.25%)
AAPL   175.04 (-2.57%)
MSFT   415.02 (-0.12%)
META   498.75 (-0.71%)
GOOGL   133.49 (-2.66%)
AMZN   177.94 (-0.16%)
TSLA   188.96 (-6.75%)
NVDA   855.60 (+3.99%)
NIO   5.40 (-6.57%)
AMD   206.96 (+2.13%)
BABA   72.02 (-3.48%)
T   16.76 (-1.30%)
F   12.80 (+2.81%)
MU   96.40 (+1.31%)
CGC   3.03 (-5.61%)
GE   160.85 (+1.39%)
DIS   113.80 (+1.65%)
AMC   4.31 (-1.15%)
PFE   25.85 (-2.78%)
PYPL   60.17 (-0.61%)
XOM   104.16 (-1.59%)

Immunovant (IMVT) Stock Price, News & Analysis

$34.84
-0.46 (-1.30%)
(As of 03:40 PM ET)
Today's Range
$33.73
$35.85
50-Day Range
$34.93
$44.19
52-Week Range
$14.05
$45.58
Volume
881,064 shs
Average Volume
1.25 million shs
Market Capitalization
$5.06 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.73

Immunovant MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
38.0% Upside
$47.73 Price Target
Short Interest
Bearish
14.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.86mentions of Immunovant in the last 14 days
Based on 7 Articles This Week
Insider Trading
Selling Shares
$659,896 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($1.73) to ($1.85) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.62 out of 5 stars

Medical Sector

477th out of 948 stocks

Biological Products, Except Diagnostic Industry

78th out of 158 stocks


IMVT stock logo

About Immunovant Stock (NASDAQ:IMVT)

Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.

IMVT Stock Price History

IMVT Stock News Headlines

IMVT Mar 2024 36.000 call
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Immunovant, Inc. (NASDAQ:IMVT) CFO Sells $105,919.50 in Stock
Immunovant Inc CFO Eva Barnett Sells 2,930 Shares
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Recap: Immunovant Q3 Earnings
Immunovant, Inc. (IMVT)
Immunovant: An Intriguing And Developing Story
Should You Invest in Immunovant (IMVT)?
Immunovant Inc CFO Eva Barnett Sells 3,515 Shares
See More Headlines
Receive IMVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunovant and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
3/04/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
5/27/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:IMVT
Fax
N/A
Employees
164
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.73
High Stock Price Target
$57.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+35.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
15 Analysts

Profitability

Net Income
$-210,960,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.68 per share

Miscellaneous

Free Float
138,319,000
Market Cap
$5.13 billion
Optionable
Optionable
Beta
0.67
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














IMVT Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunovant stock right now?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Immunovant in the last twelve months. There are currently 15 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" IMVT shares.
View IMVT analyst ratings
or view top-rated stocks.

What is Immunovant's stock price target for 2024?

15 equities research analysts have issued 12-month target prices for Immunovant's stock. Their IMVT share price targets range from $32.00 to $57.00. On average, they expect the company's share price to reach $47.73 in the next twelve months. This suggests a possible upside of 38.0% from the stock's current price.
View analysts price targets for IMVT
or view top-rated stocks among Wall Street analysts.

How have IMVT shares performed in 2024?

Immunovant's stock was trading at $42.13 at the beginning of the year. Since then, IMVT shares have decreased by 17.9% and is now trading at $34.58.
View the best growth stocks for 2024 here
.

Are investors shorting Immunovant?

Immunovant saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 9,010,000 shares, an increase of 8.4% from the January 31st total of 8,310,000 shares. Based on an average daily volume of 1,510,000 shares, the days-to-cover ratio is presently 6.0 days. Approximately 14.8% of the shares of the company are short sold.
View Immunovant's Short Interest
.

When is Immunovant's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 27th 2024.
View our IMVT earnings forecast
.

How were Immunovant's earnings last quarter?

Immunovant, Inc. (NASDAQ:IMVT) posted its earnings results on Monday, February, 12th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.43) by $0.07.

What other stocks do shareholders of Immunovant own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunovant investors own include Salesforce (CRM), NVIDIA (NVDA), Advanced Micro Devices (AMD), Walt Disney (DIS), Fulcrum Therapeutics (FULC), Myovant Sciences (MYOV), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), JD.com (JD) and Johnson & Johnson (JNJ).

Who are Immunovant's major shareholders?

Immunovant's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.03%), Point72 Asset Management L.P. (1.84%), Perceptive Advisors LLC (1.60%), Price T Rowe Associates Inc. MD (1.11%), Price T Rowe Associates Inc. MD (1.10%) and Armistice Capital LLC (0.99%). Insiders that own company stock include Atul Pande, Douglas J Hughes, Eva Renee Barnett, Frank Torti, George V Migausky, Julia G Butchko, Mark S Levine, Peter Salzmann, Sciences Ltd Roivant and William L Macias.
View institutional ownership trends
.

How do I buy shares of Immunovant?

Shares of IMVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMVT) was last updated on 3/4/2024 by MarketBeat.com Staff